Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Rituximab and Methotrexate in Newly-diagnosed PCNSL
ChiCTR1900027811Phase 2Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, rituximab and methotrexate in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Xuanwu Hospital. Primary endpoint: Overall response rate. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
ibrutinibrituximabmethotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900027811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027811.